- Home
- BAX
as 11-15-2024 3:31pm EST
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.
| Founded: | 1931 | Country: | United States |
| Employees: | N/A | City: | DEERFIELD |
| Market Cap: | 17.3B | IPO Year: | N/A |
| Target Price: | $41.40 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.21 | EPS Growth: | -95.85 |
| 52 Week Low/High: | $31.60 - $44.01 | Next Earning Date: | 11-08-2024 |
| Revenue: | $15,062,000,000 | Revenue Growth: | 32.37% |
| Revenue Growth (this year): | 3.81% | Revenue Growth (next year): | 3.45% |
Latest Baxter International Inc. News
BAX Breaking Stock News: Dive into BAX Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Baxter to Present at Jefferies London Healthcare Conference
GuruFocus.com
4 days ago
Decoding Baxter International Inc (BAX): A Strategic SWOT Insight
Business Wire
5 days ago
Baxter to Present at Stifel 2024 Healthcare Conference
MT Newswires
5 days ago
UBS Cuts Price Target on Baxter International to $38 From $40, Maintains Neutral Rating
Business Wire
6 days ago
Baxter Declares Quarterly Dividend
MT Newswires
6 days ago
Stifel Adjusts Price Target on Baxter International to $38 From $46, Maintains Buy Rating
MT Newswires
6 days ago
Deutsche Bank Adjusts Baxter International Price Target to $35 From $42
MT Newswires
6 days ago
Citigroup Adjusts Price Target on Baxter International to $37 From $40, Maintains Neutral Rating
Compare BAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BAX Baxter International Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.